A Phase 1 Study of RGT-61159 in People With Adenoid Cystic Carcinoma

Full Title

A Phase 1a/1b, First-in-human, Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients with Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Purpose

In this study, researchers want to find the best dose of RGT-61159 to treat salivary gland cancer. The people in this study have adenoid cystic carcinoma that came back or keeps growing after treatment.

RGT-61159 is called an mRNA degrader. mRNA is present in all living cells and plays a role in making proteins. Your type of cancer has high levels of the MYB protein, which can cause cancer cells to grow.

RGT-61159 reduces the MYB mRNA and protein. This action may help slow or stop the growth and spread of cancer cells. RGT-61159 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have adenoid cystic carcinoma that came back or keeps growing even though you had treatment.
• Have recovered from the serious side effects of prior therapies before taking RGT-61159.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Alan Ho’s office at 646-541-7062.